August 25, 2008 Sweden
Diamyd update on Phase III trials with Diamyd®
European
Investigator's Meeting in Stockholm
18-19th of September
On the 18-19th of September, Diamyd is hosting an Investigator's
Meeting
for diabetes teams from 20-30 European clinics from several countries,
which will
take part in the European Phase III study with the Diamyd®
diabetes
vaccine for new onset type 1 diabetes patients. The trial will enrol
more than
300 patients. Gathering all investigators in one place will ensure the
trial is
carried out in a uniform way across all sites and countries. A similar
meeting
was held in April for all the Swedish Investigators which was very
successful.
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.